Kentucky 2026 Regular Session

Kentucky House Bill HB729

Introduced
2/25/26  
Refer
2/25/26  

Caption

AN ACT relating to pharmaceutical drug safety and declaring an emergency.

Impact

The impact of HB729 on state laws is significant, as it amends various statutes to enhance the capability of the Board of Pharmacy, thereby improving accountability and safety in pharmaceutical practices. The act declares an emergency, allowing it to take effect immediately upon passage, which underscores the urgency perceived by lawmakers regarding drug safety. The changes introduce new regulations for prescription records, drug storage standards, and compounding practices, all with the goal of safeguarding the public from harm. It represents a proactive approach to tackling issues related to unsafe drug practices and the integrity of medications distributed in Kentucky.

Summary

House Bill 729, known as Jimmie's Law, is a legislative act aimed at enhancing pharmaceutical drug safety in Kentucky. The bill outlines various amendments to existing laws concerning the regulation and oversight of pharmaceuticals, seeking to ensure the safety of the drug supply chain. Among its provisions, HB729 empowers the Kentucky Board of Pharmacy to enforce stricter regulations and inspection protocols, which are deemed essential to protect public health against counterfeit or unsafe drugs. The bill emphasizes the importance of establishing standards for the pharmacy profession and reinforces the board's authority in overseeing compliance with drug safety requirements.

Sentiment

Sentiment around HB729 is largely positive among health professionals and regulatory bodies, reflecting a consensus on the necessity of ensuring high standards in pharmaceutical care. Proponents laud the bill as a substantial step forward in protecting patients and ensuring the effectiveness of medications. However, some opposition has emerged from stakeholders concerned about the increased regulatory burden on pharmacies and potential implications for patient access to medications. Despite these concerns, the prevailing view is that the safeguards provided by the bill outweigh the challenges posed by its implementation.

Contention

Notable points of contention include discussions around the balance between regulatory oversight and accessibility of pharmaceuticals. Critics argue that overly stringent regulations could hinder pharmacists' ability to respond flexibly to patient needs and complicate the delivery of care. Moreover, the provisions outlining emergency refills and changes in compounding practices have raised questions about how these measures will impact pharmacy operations. Stakeholders emphasize the need for careful implementation to avoid unintended consequences that might restrict patient access to essential medications, which is at the heart of the legislative debate surrounding HB729.

Companion Bills

No companion bills found.

Previously Filed As

KY HB614

AN ACT relating to professional dispensing fees for prescription drugs and declaring an emergency.

KY HB501

AN ACT relating to pharmaceutical drugs.

KY HB772

AN ACT relating to pharmaceutical manufacturers.

KY HB695

AN ACT relating to the Medicaid program and declaring an emergency.

KY SB14

AN ACT relating to pharmaceutical manufacturers.

KY HB90

AN ACT relating to maternal health and declaring an emergency.

KY HB648

AN ACT relating to liability shield products and declaring an emergency.

KY HB389

AN ACT relating to prescription drugs.

KY HB515

AN ACT relating to the Office of Safer Communities, making an appropriation therefor, and declaring an emergency.

KY HB140

AN ACT relating to public health and safety.

Similar Bills

No similar bills found.